Altria reported modest year-over-year EPS growth of 2.5% in Q4 2025, driven by a 4.3% increase in average cigarette pricing that more than offset a 3.1% decline in shipment volumes. The company generated $1.8 billion in operating cash flow during the quarter, enabling $750 million in share repurchases and supporting a nearly 7% dividend yield that is covered more than 1.8 times by free cash flow. Management reiterated its target of maintaining leverage below 3.5x net debt to adjusted EBITDA, preserving financial flexibility for dividend sustainability through 2028.

Altria advanced its smoke-free strategy with the recent FDA marketing authorization for its nicotine pouch product, marking the first such approval for the U.S. oral nicotine category. During Q4, oral tobacco revenues grew 9.7% year-over-year, contributing $210 million to segment sales, while heated tobacco device trial rates increased by 25% in select test markets. The company also completed the acquisition of a minority stake in a leading vapor products firm for $300 million, strengthening its portfolio of reduced-risk offerings.

Following Q4 results, several research firms upgraded Altria’s rating to Buy, citing a forward P/E in the mid-low teens that reflects a roughly 10% discount to peer tobacco multiples. Analysts now project adjusted diluted EPS growth of 5% annually through 2028 and anticipate dividend increases of 4% per year over the same period. Conversely, one major house moved to Hold, citing Marlboro’s volume market share slipping below 40% in Q4 and smoke-free revenues remaining under 15% of total tobacco sales, underscoring execution risks in the transition.